Rebecca Brown, MD, discusses how the NCCN guideline inclusion of brigatinib is changing clinical practice for NF2-related schwannomatosis.
Rebecca Brown, MD, PhD
Advertisement
Rebecca Brown, MD, PhD, is an associate professor in Neuro-Oncology at the University of Alabama at Birmingham
Articles by Rebecca Brown, MD, PhD
Rebecca Brown, MD, PhD, discusses neuroendocrine tumors.
Advertisement
Latest Updated Articles
Explaining How Brigatinib May Work in SchwannomatosisSeptember 24th 2026
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
AUA Releases Guideline Amendment for NMIBC
4
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
5